Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
REGULATORY
3 Pharma Groups Push Chuikyo to Expand PMP Coverage, Scrap Company Criteria
Three major pharma trade groups of Japan, the US, and Europe on July 24 made their proposals towards Japan’s next drug pricing reform scheduled for April 2020, calling for reconsidering product and company criteria introduced in 2018 for the price…
To read the full story
Related Article
- Chuikyo Snubs Industry Request to Revisit Comparator Criteria in New Drug Pricing
October 24, 2019
- Chuikyo Positive to Add Sakigake Drugs for PMP Coverage, Nudges Industry to Show Counterproposal for Company Criteria
October 10, 2019
- Industry’s Plea to Scrap PMP Company Criteria Gets Cold Shoulder at Chuikyo
July 25, 2019
REGULATORY
- LDP’s Patch League Urges Finance Minister to Continue Coverage, Support Prices
December 16, 2025
- Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests
December 15, 2025
- LDP Leans Towards “Special Charges” for OTC-Like Drugs, Not Coverage Removal
December 15, 2025
- Ishin Urges “Special Charge” Scheme for OTC-Like Drugs, Eyes FY2026 Launch
December 15, 2025
- LDP Tax Panel OKs New 40% R&D Credit for Strategic Technologies
December 12, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…